SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
about
When to start antiretroviral therapy: as soon as possiblePharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study dataMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Abacavir/lamivudine combination in the treatment of HIV: a review.Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trialHypersensitivity reactions to HIV therapy.Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersInterpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patientsTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.Fosamprenavir: advancing HIV protease inhibitor treatment options.Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Antiretroviral therapy in advanced HIV-1 infection.Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Fosamprenavir: drug development for adherence.A review of nelfinavir for the treatment of HIV infection.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.Fosamprenavir calcium plus ritonavir for HIV infection.Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cellsPharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.HIV-related liver disease: ARV drugs, coinfection, and other risk factors.Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.HIV protease inhibitors: recent clinical trials and recommendations on use.Causes and consequences of incomplete HIV RNA suppression in clinical trials.Abacavir and lamivudine combination.Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
P2860
Q27006767-0883E80B-9D44-4A17-8531-75F959F8ABBCQ30652267-BAD9865B-72D6-49B6-AD31-5C3E1CF331CDQ33258171-6E7DD4B6-C402-473D-996A-E7130E7A67EFQ33715435-A6831A7A-ADF5-4C3E-AACF-DA6A743F117AQ34509848-D49D3B8A-4CF4-46F4-A8FA-083E87946337Q34510595-DCB92F39-2F04-4147-8089-A8000530A3DBQ34631149-430DE031-1E86-41A5-802A-CC7D19542A5AQ34713094-A744121D-67E8-4DA4-B28A-2B763456971FQ34848294-76472CBD-9696-4B0D-BD6E-0D082D7D607FQ34976463-5B6CA2B6-C098-4B6C-A386-8222FE0712A5Q35636050-D52AA520-3DA5-4EFE-B0EA-8C2D90688C1BQ35758975-2646042F-9EC5-478B-AF57-AA66597F9AFEQ35792853-441C6A3F-50A4-47B7-8CCA-D48E79B58914Q35871889-E374C461-9269-4907-837F-D264CA8E75A1Q35912640-3A1B20AF-4796-470C-B961-36B488845F53Q35963960-BE78D528-6531-48A5-978E-E7F34EC511C7Q36120482-12E20FEA-FEF1-41CC-ACF4-F792522293F0Q36285950-F6ED3235-2C30-4657-9EA2-C2AFEDEA4EFDQ36295462-79E35372-96CE-4BE2-9728-D8B9752DA927Q36322100-CC2AF5EA-85FE-4A76-AF62-D644026C0F5FQ36498882-CF3B0BD1-A0FE-443F-BFC2-B2EC948C1F1EQ36546278-38105318-8D02-4143-910D-67E880FB1495Q36653838-EEE76577-B740-42B1-82DD-BE1654ED2384Q36675417-D7647191-08CE-4F54-8F2E-D8D8689456B6Q36839698-E182D438-F315-4649-9885-2A6249A61F40Q36993465-D4AC87E2-8AA8-4564-B5AD-2EC34D87D041Q37111827-1C9BB22D-5DC2-45F0-8ECE-002BB6B7D277Q37228748-CD8301FB-2925-42B1-8012-699D7FEC3B77Q37274775-B2C26FD5-91CD-40E1-960F-58B20775A653Q37335653-557F72E8-5F11-4547-A868-C8F9AC802091Q37391122-17BE26FF-C4D0-4AD9-B310-D9A536515A32Q37428827-102C7CA0-D28E-45DE-B607-57A165736FABQ37439512-A56D6075-8811-4B58-8C30-02CF35838FCDQ37519715-332C3EA1-1637-43D7-8131-4B5D733E7D0EQ37631282-B3EC59AE-D582-490F-A32C-94AE29317B62Q37636061-F7B09745-B225-41DF-A8BB-7C9F0F941C3EQ37692734-911F7B34-8E2E-424E-AFD2-2FA48A9EA485Q37782179-78BCA9F7-881F-4C39-A8D9-782AE34B35A9Q38291064-DBCD6428-5CFF-476F-90B0-347791FFDF80Q41969970-C5F8389B-11E9-4EC9-A872-077B928496FB
P2860
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@en
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@nl
type
label
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@en
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@nl
prefLabel
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@en
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@nl
P2093
P1433
P1476
SOLO: 48-week efficacy and saf ...... naive HIV-1-infected patients.
@en
P2093
Andrzej Gladysz
Cindy Garris
Dirk Schürmann
Edwin DeJesus
Joseph C Gathe
Nicholaos C Bellos
Prudence Ive
P304
P356
10.1097/01.AIDS.0000131332.30548.92
P407
P50
P577
2004-07-01T00:00:00Z